Takeda Pharmaceuticals shares were trading down more than 7% on Thursday, following the company’s initial public offering and the filing of a lawsuit.
The stock’s price dropped nearly 25% from its high of $21.10 on Nov. 3.
Takeda’s stock price has also been trending lower since the filing.
The company reported a $1.8 billion loss in the first quarter, down from $3.1 billion in the same period last year.
Takedas stock price was down more this quarter than in any previous quarter since its debut in 2008.
The company has been grappling with growing concerns about the safety of its opioid injectors.
The injectors, used to treat pain and manage seizures, were designed to be used in conjunction with a drug called Nexium that can be used as a nasal spray and injected intravenously.
Takena is developing a drug that can use the injectors as a treatment for people with pain without being administered the drug.
Takena’s lawsuit is a separate issue from a separate lawsuit filed against Takedo on Monday, alleging the company failed to report its losses on time.
The filing also alleges Takedos stock price is volatile because of the ongoing legal battle with the Drug Enforcement Administration over the sale of the injector.
Tooka has a history of lawsuits involving its injectors that have been settled in court.
The U.S. District Court for the District of Columbia last year ruled that the company did not have to disclose its financial results for the first nine months of 2016.
Tired of being sued by the FDA?
Takedo is trying to move forward with a lawsuit that could result in billions of dollars in fines and other penalties against the company.
Tooka announced its first lawsuit in 2016.
The suit seeks class-action status for anyone who bought Takeds injectors for themselves or others.